Litcius/Paper detail

LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study

Lin Shen, Z-H. Lu, Jann‐Yuan Wang, Y-Q. Shu, L. Kong, Lin Yang, B-H. Wang, Wang Zw, Ji Yh, Guodo Cao, H. Liu, T-J. Cui, N. Li, Qiu Ws, Z. Ma, Yi‐Lang Chen, HY Li, Xinchen Sun, Y. Wang, Han Zhou

2021Annals of Oncology36 citationsDOI

Topics & Concepts

MedicineChemotherapyOncologyInternal medicineEsophageal cancerEsophageal squamous cell carcinomaCancerBasal cellEsophageal Cancer Research and TreatmentRadiopharmaceutical Chemistry and ApplicationsLung Cancer Treatments and Mutations
LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study | Litcius